HK1209342A1 - 用於在治療性功能障礙中使用的 腺苷受體配體 - Google Patents

用於在治療性功能障礙中使用的 腺苷受體配體

Info

Publication number
HK1209342A1
HK1209342A1 HK15110112.5A HK15110112A HK1209342A1 HK 1209342 A1 HK1209342 A1 HK 1209342A1 HK 15110112 A HK15110112 A HK 15110112A HK 1209342 A1 HK1209342 A1 HK 1209342A1
Authority
HK
Hong Kong
Prior art keywords
treatment
sexual dysfunction
receptor ligands
adenosine receptor
adenosine
Prior art date
Application number
HK15110112.5A
Other languages
English (en)
Inventor
‧菲什曼
Original Assignee
Can Fite Biopharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Can Fite Biopharma Ltd filed Critical Can Fite Biopharma Ltd
Publication of HK1209342A1 publication Critical patent/HK1209342A1/zh

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK15110112.5A 2012-08-09 2015-10-15 用於在治療性功能障礙中使用的 腺苷受體配體 HK1209342A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IL22138212 2012-08-09
IL22298812 2012-11-12
PCT/IL2013/050675 WO2014024195A1 (en) 2012-08-09 2013-08-08 A3 adenosine receptor ligands for use in treatment of a sexual dysfunction

Publications (1)

Publication Number Publication Date
HK1209342A1 true HK1209342A1 (zh) 2016-04-01

Family

ID=49003954

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15110112.5A HK1209342A1 (zh) 2012-08-09 2015-10-15 用於在治療性功能障礙中使用的 腺苷受體配體

Country Status (13)

Country Link
US (1) US9549943B2 (zh)
EP (2) EP2892533A1 (zh)
JP (1) JP6140825B2 (zh)
KR (1) KR101971762B1 (zh)
CN (1) CN104619323B (zh)
AU (1) AU2013301125B2 (zh)
BR (1) BR112015002697A8 (zh)
CA (1) CA2880753C (zh)
HK (1) HK1209342A1 (zh)
IL (1) IL237107B (zh)
MX (1) MX2015001644A (zh)
RU (1) RU2015105407A (zh)
WO (1) WO2014024195A1 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115779089A (zh) * 2022-11-28 2023-03-14 中国医学科学院肿瘤医院 用于治疗或改善雄性癌症及抑制其细胞系的药物的相关应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4788966A (en) 1987-05-14 1988-12-06 Inbae Yoon Plug for use in a reversible sterilization procedure
US5443836A (en) 1993-03-15 1995-08-22 Gensia, Inc. Methods for protecting tissues and organs from ischemic damage
US5773423A (en) 1993-07-13 1998-06-30 The United States Of America As Represented By The Department Of Health And Human Services A3 adenosine receptor agonists
US5688774A (en) * 1993-07-13 1997-11-18 The United States Of America As Represented By The Department Of Health And Human Services A3 adenosine receptor agonists
AU1399297A (en) 1996-01-24 1997-08-20 Sumitomo Chemical Company, Limited Dihalopropene compounds, their use as insecticides/acaricides and intermediates for their production
DE69808440T2 (de) * 1997-03-07 2003-07-10 Vernalis Res Ltd Verwendung von (+)mefloquine zur behandlung von malaria
JP2003517423A (ja) 1997-07-29 2003-05-27 メドコ リサーチ、インコーポレイテッド アデノシンレセプターモジュレーターとしてのn6−置換アデノシン−5′−ウロナミド
US6048865A (en) 1997-07-29 2000-04-11 Medco Research, Inc. N6 -substituted-adenosine-5'-uronamides as adenosine receptor modulator
WO1999020284A1 (en) 1997-10-23 1999-04-29 Trustees Of The University Of Pennsylvania Methods for reducing ischemic injury of the heart via the sequential administration of monophosphoryl lipid a and adenosine receptor agents
IL133680A0 (en) 1999-09-10 2001-04-30 Can Fite Technologies Ltd Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist
JP4012070B2 (ja) * 2001-01-16 2007-11-21 カン−フィテ・バイオファーマ・リミテッド ウイルスの複製を阻害するためのアデノシンa3受容体アゴニストの使用
CA2440141A1 (en) * 2001-03-06 2002-09-12 Cellegy Pharmaceuticals, Inc. Compounds and methods for the treatment of urogenital disorders
US20030143282A1 (en) * 2002-01-28 2003-07-31 Pnina Fishman Adenosine A3 receptor agonist
WO2004086034A2 (en) * 2003-03-28 2004-10-07 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g-protein-coupled receptor adenosine a3(adora3)
WO2007045989A1 (en) 2005-10-20 2007-04-26 Pfizer Limited Pyridyl derivatives useful as h3 ligands
EP1945639A1 (en) * 2005-11-04 2008-07-23 Pfizer Limited Tetrahydronaphthyridine derivative
KR101383228B1 (ko) * 2006-01-26 2014-04-09 더 가번먼트 오브 더 유나이티드 스테이츠 오브 아메리카, 레프리젠티드 바이 더 세크러터리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비스즈 A3 아데노신 수용체 알로스테릭 조절제
WO2008066627A2 (en) * 2006-10-24 2008-06-05 Board Of Regents, The University Of Texas System Adenosine signaling in diagnosis, treatment and prevention of priapism and erectile dysfunction
WO2009006089A2 (en) * 2007-06-29 2009-01-08 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services A2 adenosine receptor agonists

Also Published As

Publication number Publication date
BR112015002697A2 (pt) 2017-10-31
JP6140825B2 (ja) 2017-05-31
EP3530273A3 (en) 2020-02-26
MX2015001644A (es) 2015-08-14
IL237107B (en) 2019-11-28
CA2880753C (en) 2019-09-10
RU2015105407A (ru) 2016-10-10
AU2013301125A1 (en) 2015-02-12
JP2015524465A (ja) 2015-08-24
IL237107A0 (en) 2015-03-31
BR112015002697A8 (pt) 2018-01-16
US9549943B2 (en) 2017-01-24
KR20150042232A (ko) 2015-04-20
CA2880753A1 (en) 2014-02-13
US20150216889A1 (en) 2015-08-06
CN104619323A (zh) 2015-05-13
CN104619323B (zh) 2018-03-09
EP3530273A2 (en) 2019-08-28
EP2892533A1 (en) 2015-07-15
KR101971762B1 (ko) 2019-08-13
AU2013301125B2 (en) 2018-03-15
WO2014024195A1 (en) 2014-02-13

Similar Documents

Publication Publication Date Title
EP2726048A4 (en) SEXUAL STIMULATION DEVICE
GB201119608D0 (en) Stimulation apparatus
GB201114212D0 (en) Therapeutic agents
EP2752333A4 (en) SEAT APPARATUS
AU338103S (en) Therapeutic device for stimulating muscle contractions
GB201119401D0 (en) Therapeutic agents
EP2789326A4 (en) MASSAGE DEVICE
HK1204325A1 (zh) 用於治療性功能障礙的 檸檬苦素類化合物
HK1202412A1 (zh) 揉背裝置
ZA201502595B (en) Therapeutic methods
EP2777680A4 (en) DEVICE FOR FEMALE SEXUAL STIMULATION
EP2777679A4 (en) DEVICE FOR MALE SEXUAL STIMULATION
EP2910234A4 (en) HYDRAULIC MASSAGE DEVICE
EP2734158A4 (en) STIMULATING DEVICE
EP2688566A4 (en) ANTICANCER THERAPEUTIC AGENTS
GB201113000D0 (en) Stimulation device
HK1209342A1 (zh) 用於在治療性功能障礙中使用的 腺苷受體配體
SG11201402226PA (en) Therapeutic agent for arthrosis
HK1211227A1 (zh) 用於女性性功能障礙的佈雷默浪丹療法
GB201303871D0 (en) Apparatus for giving pleasure to a person
PL2720533T3 (pl) Urządzenie stymulujące
EP2756849A4 (en) AGENT FOR THE PROMOTION OF REGENERATION OF A SKELETAL MUSCLE
GB201206306D0 (en) Therapeutic apparatus
GB201105843D0 (en) Securing device to person
GB201119736D0 (en) Muscle stimulation